Literature DB >> 19054591

Lung cancer in patients aged 80 years and over.

Hiroaki Satoh1, Koichi Kurishima, Ryota Nakamura, Hiroichi Ishikawa, Katsunori Kagohashi, Gen Ohara, Shigemi Ishikawa, Morio Ohtsuka, Kiyohisa Sekizawa, Nobuyuki Hizawa.   

Abstract

OBJECTIVES: The purpose of this study is to examine clinical and pathological features, treatment modality approaches in the elderly, especially in patients aged 80 years and older.
METHODS: From the databases at two educational hospitals during the period from January 1978 and December 2007, medical records of lung cancer patients were retrospectively reviewed. The patient population was divided into three age groups: less than 70 years (the <70 age group), 70-79 years (the 70-79 age group), and 80 years or older (the > or =80 age group). Time trends were also studied in two-time intervals: first study period up to 1997, which represents past practice standards, the second study period up to 2007, which represents contemporary practice.
RESULTS: Patients aged 80 years and older comprised 7.5% of 2775 consecutive patients with lung cancer, and there was a rapid increase in the proportion of patients aged 80 years or older from the earlier to the later time period. The > or =80 age group had higher proportion of poor performance status (PS) and comorbid disease than the <70 age group and the 70-79 age group. Unchanged proportion of patients with poor PS and advanced disease at presentation were observed in the > or =80 age group. The > or =80 age group was less likely to be subjected to surgery or chemotherapy, and had inferior outcomes when compared with the 70-79 age group and the <70 age group. Survival improvement was not observed in the > or =80 age group. Multivariate analysis showed good PS, early clinical stage and surgery were favorable prognostic factors in the > or =80 age group.
CONCLUSION: In order to improve the outcome, detection of early stage lung cancer in patients with good PS and thorough pretreatment evaluation for appropriate treatment are indeed essential even for the > or =80 age group of patients.

Entities:  

Mesh:

Year:  2008        PMID: 19054591     DOI: 10.1016/j.lungcan.2008.10.020

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

1.  A model for morbidity after lung resection in octogenarians.

Authors:  Mark F Berry; Mark W Onaitis; Betty C Tong; David H Harpole; Thomas A D'Amico
Journal:  Eur J Cardiothorac Surg       Date:  2011-01-26       Impact factor: 4.191

2.  Surgical results of pancreatoduodenectomy in elderly patients.

Authors:  Shinichiro Yamada; Mitsuo Shimada; Tohru Utsunomiya; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Hiroki Mori; Mami Kanamoto; Jun Hanaoka; Shuichi Iwahashi; Yu Saitoh
Journal:  Surg Today       Date:  2012-03-24       Impact factor: 2.549

3.  Safety creatinine clearance level for platinum chemotherapy in lung cancer patients.

Authors:  Gen Ohara; Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Oncol Lett       Date:  2011-11-16       Impact factor: 2.967

4.  Lung Cancer in the Oldest Old: A Nation-Wide Study in The Netherlands.

Authors:  Karlijn J G Schulkes; Carin A M Pouw; Elisabeth J M Driessen; Leontine J R van Elden; Frederiek van den Bos; Maryska L G Janssen-Heijnen; Jan-Willem J Lammers; Marije E Hamaker
Journal:  Lung       Date:  2017-06-19       Impact factor: 2.584

Review 5.  Surgical treatment of non-small-cell lung cancer in octogenarians.

Authors:  Miguel Guerra; Paulo Neves; José Miranda
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-02-08

6.  Application of conditional probability analysis to distant metastases from lung cancer.

Authors:  Akihiro Oikawa; Hideto Takahashi; Hiroichi Ishikawa; Koichi Kurishima; Katsunori Kagohashi; Hiroaki Satoh
Journal:  Oncol Lett       Date:  2011-12-23       Impact factor: 2.967

7.  Serum levels of cystatin C in elderly lung cancer patients.

Authors:  Gen Ohara; Kunihiko Miyazaki; Koichi Kurishima; Katsunori Kagohashi; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Oncol Lett       Date:  2011-11-24       Impact factor: 2.967

8.  Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.

Authors:  Hiroyuki Nakamura; Hiroaki Satoh; Takayuki Kaburagi; Yoshihiro Nishimura; Yoko Shinohara; Masaharu Inagaki; Takeo Endo; Takefumi Saito; Kenji Hayashihara; Nobuyuki Hizawa; Koichi Kurishima; Takeshi Nawa; Katsunori Kagohashi; Koji Kishi; Hiroichi Ishikawa; Hideo Ichimura; Toshio Hashimoto; Yukio Sato; Mitsuaki Sakai; Koichi Kamiyama; Takeshi Matsumura; Koji Unoura; Kinya Furukawa
Journal:  Med Oncol       Date:  2012-11-02       Impact factor: 3.064

9.  Cluster analysis of deterioration sites after first-line epidermal growth factor receptor-tyrosine kinase inhibitor in epidermal growth factor receptor mutated non-small cell lung cancer.

Authors:  Shinichiro Okauchi; Kunihiko Miyazaki; Hiroaki Satoh
Journal:  Contemp Oncol (Pozn)       Date:  2022-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.